Dashboard/Countries/🇵🇰 Pakistan
Critical — HIVET initial term expired Dec 2024

🇵🇰 Pakistan

2 signed distribution agreements (HIVET, UMEX). HIVET initial 3-year term expired 1 Dec 2024 and is operating under stacked LOA layers. UMEX has an internally contradictory dispute clause (Art. 24).

Country profile GAP — not in country notes

Pakistan — regulatory context

GAP. Pakistan is not yet in the counterparty-country-notes.md reference (the file currently covers MENA, South Asia ex-Pakistan, Southeast Asia, Latin America, Africa, Central Asia/Caucasus, Russia/EAEU). The data below is sourced from the deep reviews of the HIVET and UMEX contracts — verify all items with Pakistani local counsel before relying on them for action.

Vet drug authority
DRAP (Drug Regulatory Authority of Pakistan). Registration via local importer/distributor; foreign principals cannot register directly.
Commercial agency law
Pakistan Contract Act 1872 + Sales of Goods Act 1930. No specific commercial-agency protection statute. Sole-proprietorship counterparties carry no corporate-veil protection.
FX rules
State Bank of Pakistan (SBP) controls; repatriation typically via authorised dealer; documentation requirements heavy. Pakistan has chronic FX shortages.
Stamp duty
Stamp Act 1899 — provincial rates; non-stamped contracts inadmissible until stamped + penalty.
Multi-distributor permissibility
YES (GAP — verify) Likely permitted — Contract Act 1872 governs without statutory restriction. Verify with Pakistani local counsel that competition-law abuse review (Competition Commission of Pakistan) does not apply.
Voidance risks
  • Stamp Act 1899: provincial stamp duty applies; non-stamping = inadmissible in evidence. Confirm rate in province of execution.
  • Sole-proprietorship counterparty risk: no corporate veil; counterparty death/incapacity = no continuity.
  • DRAP registration in importer's name: MA must be held by Pakistani local entity; transferable on termination.
  • Language: Urdu / English commonly used; English contracts enforceable.
  • Formalities: Pakistan is NOT a Hague Apostille member — consular legalization typically required for foreign documents.
  • FX risk: SBP allocation queues can hold up payment.
GAPS to verify with Pakistani local counsel
(i) HIVET Pte Ltd incorporation pathway for sole-proprietorship conversion under Companies Act 2017; (ii) Stamp Act 1899 current provincial rates; (iii) DRAP transfer-back logistics and timelines.
Signed contracts in this country

HIVET Animal Health Business — INITIAL TERM EXPIRED

Counterparty
M/S Hivet Animal Health Business
Signatory
Dr. Asif Masood Rana (Proprietor)
Entity form
Sole proprietorship — no corporate veil; single point of failure
Effective
1 December 2021
Term end (initial)
EXPIRED 1 Dec 2024 — 528 days ago
Operating status
Under stacked LOA layers: 01.01.2025; 13.11.2025; 19.12.2025 (HIVET); 19.12.25 (HIVET International)
Score / grade
56 / 100C
Deep review
Open the deep-review dashboard ›

Top 3 issues

  1. Sole-proprietorship counterparty — single point of failure (Dr. Asif's death/incapacity = no continuity).
  2. Art. 33.2 pathological dispute clause (BANI Rules + SIAC seat — internally inconsistent).
  3. LIBOR (Art. 8.3) defunct since 30 June 2023 — late-payment interest clause non-functional.

Authorized Products (current LOA)

Operating under stacked LOA layers: 01.01.2025; 13.11.2025; 19.12.2025 (HIVET); 19.12.25 (HIVET International). Base SKUs:

#ProductStrainDose
1Vaksimune NDLSND Lasota1000 ds
2Vaksimune ND Clone IBND Clone + IB1000 ds
3Vaksimune IBD M+IBD intermediate-plus1000 ds
4Vaksimune IBD LIBD live1000 ds
5Vaksimune Coryza LECoryza multi-strain1000 ds
6Vaksimune ND L InaktifND inactivated1000 ds

UMEX Biopharma (Pvt) Ltd

Counterparty
UMEX Biopharma (Pvt) Ltd
Signatory
Ammar Malik (Director — sole signatory; no board resolution on file)
Effective
14 October 2024
Term end
13 October 2027 (3 years)
Score / grade
60 / 100C
Template
Variant: annex-based, 22 articles
Commercial scale
~USD 1.02M over 3 years (flat 0% escalator)
Deep review
Open the deep-review dashboard ›

Top 3 issues

  1. Art. 24 internally contradictory — (b) Indonesian courts exclusive jurisdiction CONTRADICTS (c)-(f) SIAC arbitration mandate.
  2. Art. 5 silent payment clause (one sentence) — no LC, no advance, no terms; Pakistan SBP FX exposure.
  3. One-way indemnity (Art. 20) — UMEX→JAPFA only; no JAPFA-side cap; no reciprocal scope.

Authorized Products (current LOA)

Per Annex 2 of the signed Distribution Agreement. Schedule covers 3-year term.

#ProductStrainDose
1Vaksimune NDLSND Lasota1000 ds
2Vaksimune ND Clone IBND Clone + IB1000 ds
3Vaksimune IBD M+IBD intermediate-plus1000 ds
4Vaksimune IBD LIBD live1000 ds
5Vaksimune Coryza LECoryza multi-strain1000 ds
6Vaksimune ND L InaktifND inactivated1000 ds
7Vaksimune AI Multi (H5+H9)AI multivalent1000 ds
Country watch items

HIVET — CRITICAL

Initial 3-year term EXPIRED 1 Dec 2024 — operating under LOA layers. Sole-proprietorship counterparty (no corporate veil). Pharmacovigilance Agreement missing. LIBOR (Art. 8.3) defunct. Deep review completed.

Action: Reservation-of-rights letter on Azzalea (Art. 16.13); 90-day side-deed; demand HIVET Companies Act 2017 conversion before Dec 2026 LOA cycle; pivot to UMEX if no commitment.

UMEX — HIGH

Art. 24 internally contradictory (Indonesian courts vs SIAC). Art. 5 silent payment clause (no LC, no advance). Sole-Director signature no board resolution. Deep review completed.

Action: Amendment No. 1 within 30 days — fix Art. 24, add KUHPerdata 1266/1267 waiver, restructure Art. 5 with LC, reciprocal indemnity + 12-month cap; obtain UMEX board resolution + SECP Form-29.

Suggested actions ranked by urgency
HIVET — Today
  1. Reservation-of-rights letter on Azzalea sub-distribution consent gate (Art. 16.13) — no evidence Vaksindo consented. Owner: Legal Lead.
HIVET — 30 days
  1. Engage Pakistani counsel on (i) HIVET Pte Ltd incorporation pathway, (ii) Stamp Act 1899 status, (iii) DRAP transfer-back logistics.
HIVET — 60 days side-deed
  1. Replace Art. 33.2 hybrid BANI/SIAC clause.
  2. Add KUHPerdata 1266/1267 waiver.
  3. Attach Pharmacovigilance Agreement (Annex C).
  4. Attach Schedule B trademarks.
  5. Replace LIBOR (Art. 8.3) with Term SOFR + 2.5%.
  6. Add FCPA / sanctions / UU-PDP reps.
  7. Add 60-day MA transfer-back deadline + LD.
  8. Execute Bahasa Indonesia counterpart.
HIVET — 90 days & Annual
  1. Demand HIVET Companies Act 2017 conversion commitment; if no commitment, prepare to pivot Pakistan distribution to UMEX on next LOA cycle (Dec 2026).
  2. Annual: sanctions screening of Dr. Asif Masood Rana personally + KYC update.
UMEX — Amendment No. 1 (30 days)
  1. Replace Art. 24(b) Indonesian courts language; preserve Art. 24(c)-(f) SIAC arbitration as single clean clause.
  2. Add KUHPerdata 1266/1267 waiver.
  3. Replace Art. 5 (silent payment clause — one sentence) with 30% advance + 70% confirmed irrevocable LC at sight.
  4. Restructure Art. 20 indemnity — currently one-way Distributor→JAPFA; add reciprocal scope-narrowed + 12-month liability cap + indirect damages excluded.
  5. Replace Art. 6(f) MA transfer-back — add 60-day deadline + DRAP-specific assistance obligation + USD 5K/Product/month liquidated damages.
  6. Tighten Art. 22 force majeure — exclude economic hardship + FX non-availability + predictable government action.
  7. Add new Art. 25 — FCPA + UK Bribery Act + Tipikor + OFAC + EU + UN sanctions + FATF reps + annual screening.
  8. Cure corporate-authority gap — obtain UMEX board resolution + Form-29/SECP confirmation of Mr. Ammar Malik signing authority.
  9. Add Art. 17 (Confidentiality) post-term survival — 5 years + indefinite for trade secrets.
  10. Restructure Annex 2 — add 10% YoY escalator + 0/2/4% tiered-discount schedule.
  11. Add 60-day price-change notice (Art. 4(b) currently allows anytime change).
  12. Execute Bahasa Indonesia counterpart with English-prevails (UU 24/2009).
  13. Apply Bea Meterai stamp duty (e-meterai).
  14. Align Art. 4 (FOB Jakarta) with Art. 8 (risk transfer at destination) — recommend FCA Jakarta + delete Art. 8 destination reference.
  15. Add notice clause + change-of-control termination right.
  16. Status check: Did UMEX hit Year-1 (Oct 2024 - Oct 2025) target of USD 340,400? If not, Art. 3(c) termination right is alive.
Drafts in progress
☑

No drafts in progress for Pakistan

Marketing agreements
☰

No marketing agreements indexed